SCHEMBL2016960

SCHEMBL2016960

Cc1ccc(O[Si](C)(C)C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.50
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
TDP1 Q9NUW8 2/20 0.44
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
TEAD4 Q15561 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
LMNA P02545 1/20 0.41
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
RELA Q04206 1/20 0.39
GAA P10253 1/20 0.38
CYP2C9 P11712 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763549 0.88 CA1 (0.39) ACHEKMT2AMEN1TDP1ALDH1A1
SCHEMBL17245006 0.85 TSHR (0.43) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL3871449 0.83 ACHE (0.50) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL3873409 0.83 ACHE (0.50) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL19601195 0.83 GAA (0.61) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL9171797 0.83 MMP13 (0.37) ACHEKMT2AMEN1TDP1NPC1
SCHEMBL15220292 0.80 ACHE (0.42) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL1039748 0.80 ACHE (0.52) ACHEKMT2AMEN1TDP1CYP3A4
SCHEMBL17881929 0.80 ESR2 (0.39) KMT2ATDP1CYP3A4NPC1RAB9A
SCHEMBL9714337 0.80 ESR2 (0.39) KMT2ATDP1CYP3A4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1760078-A1 Substituted pyrazoline compounds; methods for their preparation LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-07 EP claimed
WO-2007009710-A2 SUBSTITUTED PYRAZOLINE COMPOUNDS: METHODS FOR THEIR PREPARATION LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-25 WO claimed
US-7129311-B2 Additives to prevent degradation of alkyl-hydrogen siloxanes ARCH SPECIALTY CHEMICALS, INC. (US) 2006-10-31 US claimed
US-20060159861-A1 Additives to prevent degradation of alkyl-hydrogen siloxanes ARCH SPECIALTY CHEMICALS, INC. (US) 2006-07-20 US claimed
EP-1573086-A2 ADDITIVES TO PREVENT DEGRADATION OF ALKYL-HYDROGEN SILOXANES Arch Specialty Chemicals, Inc. (US) 2005-09-14 EP claimed
US-20040127070-A1 Additives to prevent degradation of alkyl-hydrogen siloxanes ARCH SPECIALTY CHEMICALS, INC. 2004-07-01 US claimed
WO-2004027110-A2 ADDITIVES TO PREVENT DEGRADATION OF ALKYL-HYDROGEN SILOXANES ARCH SPECIALTY CHEMICALS, INC. (US) 2004-04-01 WO claimed
US-11912731-B2 Use of silylated formiates as hydrosilane equivalents COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2024-02-27 US disclosed
US-20180094003-A1 FLAME RETARDANT FILLER INTERNATIONAL BUSINESS MACHINES CORPORATION 2018-04-05 US disclosed
US-8207156-B2 Substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-06-26 US disclosed
US-20110160181-A1 SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-06-30 US disclosed
US-7959990-B2 Adjustment of liquid crystals; oligomers, dendrimers, or polymer in solution is applied to support; crosslinking by radiation or polarized light ROLIC AG (CH) 2011-06-14 US disclosed
US-7897589-B2 Substituted pyrazoline compounds, their preparation and use as medicaments LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-03-01 US disclosed
US-20060270787-A1 Additives to prevent degradation of alkyl-hydrogen siloxanes VERSUM MATERIALS US, LLC 2006-11-30 US disclosed
US-7129311-B2 Additives to prevent degradation of alkyl-hydrogen siloxanes ARCH SPECIALTY CHEMICALS, INC. (US) 2006-10-31 US disclosed
US-20060159861-A1 Additives to prevent degradation of alkyl-hydrogen siloxanes ARCH SPECIALTY CHEMICALS, INC. (US) 2006-07-20 US disclosed
EP-1573086-A2 ADDITIVES TO PREVENT DEGRADATION OF ALKYL-HYDROGEN SILOXANES Arch Specialty Chemicals, Inc. (US) 2005-09-14 EP disclosed
US-20040127070-A1 Additives to prevent degradation of alkyl-hydrogen siloxanes ARCH SPECIALTY CHEMICALS, INC. 2004-07-01 US disclosed
WO-2004027110-A2 ADDITIVES TO PREVENT DEGRADATION OF ALKYL-HYDROGEN SILOXANES ARCH SPECIALTY CHEMICALS, INC. (US) 2004-04-01 WO disclosed
US-4642363-A Method of preparing trialkyl organo-oxysilanes DYNAMIT NOBEL AG (DE) 1987-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180094003-A1 FLAME RETARDANT FILLER PCBP1, LRBA, BICRA ACHE 432/4885KMT2A 1032/4885MEN1 3635/4885
US-11912731-B2 Use of silylated formiates as hydrosilane equivalents PFAS, EPM2A, CYP2F1 ACHE 5/4885KMT2A 1150/4885MEN1 529/4885
US-20110160181-A1 SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS PIR, SYMPK, P2RX5 ACHE 499/4885KMT2A 2846/4885MEN1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.